New hope for advanced cancer: experimental drug NB003 enters human testing

NCT ID NCT04936178

Completed Disease control Sponsor: Ningbo Newbay Technology Development Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 15 times

Summary

This early-phase trial tested an experimental drug called NB003 in 258 adults with advanced solid tumors, including a type of stomach cancer called GIST. The main goals were to check the drug's safety and find the right dose. The study was open-label, meaning everyone knew they were getting the drug. Results will help decide if NB003 should be tested further.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Asan Medical Center

Seoul, Seoul, 05505, South Korea
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Centre Léon Bérard

Lyon, Rhone, 69373, France
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 201315, China
Fujian Cancer Hospital

Fuzhou, Fujian, 350015, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150081, China
Hospital Universitari Vall d'Hebron

Barcelona, Barcelona, 08035, Spain
Hospital Universitario Fundacion Jimenez Diaz

Madrid, Madrid, 28040, Spain
Institut Gustave Roussy

Villejuif, Val de Marne, 94805, France
Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, 110042, China
Mayo Clinic

Jacksonville, Florida, 32224, United States
Memorial Sloan Kettering Cancer Center

Long Island City, New York, 11101, United States
Oregon Health & Science University (OHSU)

Portland, Oregon, 97239, United States
Peking University People's Hospital

Beijing, Beijing Municipality, 100144, China
Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch

Shanghai, Shanghai Municipality, 201315, China
Royal Marsden Hospital-London

London, London, SW36JJ, United Kingdom
Samsung Medical Center

Seoul, Seoul, 05505, South Korea
Standford University

Stanford, California, 32224, United States
Sun Yat-sen University Cancer Center

Guangzhou, Guandong, 510000, China
The Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, 210008, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266003, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China
The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guandong, 510080, China
The First Affiliated Hospital of Zhejiang University school of medicine

Hangzhou, Zhejiang, 310003, China
The Second Affiliated Hospital of Xi'An Jiaotong University

Xi'an, Shaanxi, 710004, China
The Second Hospital of Anhui Medical University

Hefei, Anhui, 230601, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, 453000, China
U T MD Anderson Cancer Center Investigational Pharmacy Services

Houston, Texas, 77030, United States
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China
West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China
Xiangya Hospital, Central South University

Changsha, Huanan, 410008, China

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR